We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation
Read MoreHide Full Article
Key Takeaways
Veeva launched Veeva AI to automate tasks and streamline decisions across its core Vault platform.
By embedding GenAI in Vault, Veeva aims to boost productivity in clinical and regulatory operations.
VEEV shares are up 34.6% YTD, outpacing the industry's 22.5% gain.
Veeva Systems (VEEV - Free Report) is expanding its capabilities by introducing Veeva AI, a generative AI layer built into its core Vault platform. This development enables life sciences companies to automate routine tasks, such as document creation, navigate large datasets more efficiently, and extract insights in real time—all within the regulatory frameworks these companies must follow. With tools like AI Agents and AI Shortcuts, Veeva is focused on embedding AI into daily operations to improve productivity and decision-making across clinical, quality, and regulatory functions.
This move enhances the long-term value of Vault, which already serves as a central platform for many pharma and biotech companies. By integrating AI directly into its infrastructure, Veeva aims to deepen customer reliance on its software, strengthening its competitive position. The company is also maintaining steady financial performance and expanding geographically, including increased adoption in China. As more life sciences firms adopt AI across their operations, Veeva is positioning itself as a key technology provider for this shift.
How Peers Are Responding
IQVIA Holdings (IQV - Free Report) is another major player investing in AI within the life sciences space. Its Orchestrated Clinical Trials platform uses AI and real-world data to improve trial planning, site selection, and patient recruitment. While Veeva focuses on software platforms, IQVIA brings together data, analytics, and services to help clients manage the entire clinical development process. Its strength lies in its broad set of capabilities and large data assets, which make it a preferred partner for large pharmaceutical companies.
Schrodinger Inc. (SDGR - Free Report) , while not a direct competitor in clinical operations or CRM, is leveraging AI in the drug discovery process. Its platform uses deep learning and molecular simulation to design and optimize drug compounds, helping clients reduce time and cost in early-stage R&D. Schrödinger’s work in AI-driven discovery, combined with partnerships with large pharma companies like Bristol Myers Squibb, makes it a strong player in a complementary area of the life sciences ecosystem.
Veeva’s Price Performance, Valuation and Estimates
Shares of VEEV have gained 34.6% in the year-to-date period compared with the industry’s growth of 22.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.25, above the industry average. VEEV carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for VEEV’s fiscal 2026 earnings implies a 15.8% rise from the year-ago period.
Image: Bigstock
VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation
Key Takeaways
Veeva Systems (VEEV - Free Report) is expanding its capabilities by introducing Veeva AI, a generative AI layer built into its core Vault platform. This development enables life sciences companies to automate routine tasks, such as document creation, navigate large datasets more efficiently, and extract insights in real time—all within the regulatory frameworks these companies must follow. With tools like AI Agents and AI Shortcuts, Veeva is focused on embedding AI into daily operations to improve productivity and decision-making across clinical, quality, and regulatory functions.
This move enhances the long-term value of Vault, which already serves as a central platform for many pharma and biotech companies. By integrating AI directly into its infrastructure, Veeva aims to deepen customer reliance on its software, strengthening its competitive position. The company is also maintaining steady financial performance and expanding geographically, including increased adoption in China. As more life sciences firms adopt AI across their operations, Veeva is positioning itself as a key technology provider for this shift.
How Peers Are Responding
IQVIA Holdings (IQV - Free Report) is another major player investing in AI within the life sciences space. Its Orchestrated Clinical Trials platform uses AI and real-world data to improve trial planning, site selection, and patient recruitment. While Veeva focuses on software platforms, IQVIA brings together data, analytics, and services to help clients manage the entire clinical development process. Its strength lies in its broad set of capabilities and large data assets, which make it a preferred partner for large pharmaceutical companies.
Schrodinger Inc. (SDGR - Free Report) , while not a direct competitor in clinical operations or CRM, is leveraging AI in the drug discovery process. Its platform uses deep learning and molecular simulation to design and optimize drug compounds, helping clients reduce time and cost in early-stage R&D. Schrödinger’s work in AI-driven discovery, combined with partnerships with large pharma companies like Bristol Myers Squibb, makes it a strong player in a complementary area of the life sciences ecosystem.
Veeva’s Price Performance, Valuation and Estimates
Shares of VEEV have gained 34.6% in the year-to-date period compared with the industry’s growth of 22.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.25, above the industry average. VEEV carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for VEEV’s fiscal 2026 earnings implies a 15.8% rise from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.